Extracellular SPARC improves cardiomyocyte contraction during health and disease

Sophie Deckx [a,b] ¶, Daniel M Johnson [b,c], Marieke Rienks [a,d], Paolo Carai [a,b], Elza Van Deel [e], Jolanda Van der Velden [e], Karin R Sipido [b] , Stephane Heymans [a,b,] ¶, Anna-Pia Papageorgiou [a,b,] ¶*

¶Authors contributed equally

[a] Department of Cardiology, Maastricht University, 6202 Maastricht, The Netherlands

[b] Department of Cardiovascular Sciences, KU Leuven, 3000 Leuven, Belgium

[c] Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, UK

[d] King's British Heart Foundation Centre, King's College London, London, UK

[e] Department of Physiology, VUmc Amsterdam, 1081 Amsterdam, The Netherlands

Running title: SPARC improves cardiomyocyte contraction

* Corresponding Author

Anna-Pia Papageorgiou
Department of Cardiology, University Hospital Maastricht
Universiteitssingel 50,
6202 AZ Maastricht
The Netherlands
Tel: +31 (0)433883347, +32 (0)16346028
anna.papageorgiou@maastrichtuniversity.nl

Abstract

Secreted protein acidic and rich in cysteine (SPARC) is a non-structural extracellular matrix protein that regulates interactions between the matrix and neighboring cells. In the cardiovascular system, it is expressed by cardiac fibroblasts, endothelial cells, and in lower levels by ventricular cardiomyocytes. SPARC expression levels are increased upon myocardial injury and also during hypertrophy and fibrosis. We have previously shown that SPARC improves cardiac function after myocardial infarction by regulating post-synthetic procollagen processing, however whether SPARC directly affects cardiomyocyte contraction is still unknown. In this study we demonstrate a novel inotropic function for extracellular SPARC in the healthy heart as well as in the diseased state after myocarditis-induced cardiac dysfunction. We demonstrate SPARC presence on the cardiomyocyte membrane where it is co-localized with the integrin-beta1 and the integrin-linked kinase. Moreover, extracellular SPARC directly improves cardiomyocyte cell shortening *ex vivo* and cardiac function *in vivo, both* in healthy myocardium and during coxsackie virus-induced cardiac dysfunction. In conclusion, we demonstrate a novel inotropic function for SPARC in the heart, with a potential therapeutic application when myocyte contractile function is diminished such as that caused by a myocarditis-related cardiac injury.

Keywords: Cardiomyocyte; Contraction; Extracellular Matrix; SPARC; Viral Myocarditis;

55 # Introduction

56 In the heart, secreted protein acidic and rich in cysteine (SPARC) is expressed by
57 endothelial cells, fibroblasts and in lower amounts by cardiomyocytes [1,2]. SPARC is a
58 collagen- and calcium- binding protein that belongs to the group of matricellular proteins.
59 Matricellular proteins are matrix components characterized by (1) their counter-adhesive
60 properties, (2) low expression levels during normal physiology but increased expression
61 during stress and (3) the non-lethal phenotypes of knockout mice [2–4]. As typical of
62 matricellular proteins, SPARC secretion occurs upon injury and at sites of remodeling in
63 the heart. Previously, our group has shown that SPARC can improve clinical outcome after
64 myocardial infarction by regulating the post-synthetic procollagen processing during
65 fibrosis [5]. We showed how overexpression of SPARC could lead to an improved survival
66 and increased cardiac contraction, as measured by echocardiography, after myocardial
67 infarction in mice. Surprisingly, also in sham-operated mice, an increase in cardiac
68 fractional shortening (FS) and ejection fraction was seen when SPARC was overexpressed.
69 Yet whether SPARC directly affected cardiomyocyte contraction remained undetermined
70 [5]. Therefore, the main aim of the present study was to investigate the potential
71 inotropic function for SPARC in the healthy heart. Furthermore, as compromised cardiac
72 contractile function is a hallmark of multiple cardiac diseases, we were also interested to
73 investigate the therapeutic potential of SPARC in these conditions. For these reasons, a
74 viral myocarditis (VM) model was utilized.
75

76 VM is an important inflammatory heart disease and an etiological precursor of dilated
77 cardiomyopathy, (acute) heart failure and sudden cardiac death in young healthy
78 individuals. Up to 60% of patients with dilated cardiomyopathy and myocarditis are virus-
79 positive [6], yet diagnosis of VM is difficult due to its heterogeneous clinical presentation.
80 Viral infection of the heart causes acute myocarditis, which can progress into chronic
81 myocarditis causing cardiomyocyte damage and death, and initiation of remodeling
82 processes such as fibrosis. All of these processes ultimately result in decreased contractile
83 function of the heart as well as arrhythmia genesis and cardiac failure. Various viruses can
84 cause viral myocarditis, including parvovirus B19, enteroviruses, hepatitis C virus and
85 cytomegalovirus. The most studied are the coxsackie B viruses (CVB), which are members
86 of the enteroviruses, and are often identified in biopsies from failing viral myocarditis
87 hearts [7]. So far, research and development of novel therapeutic strategies for viral
88 myocarditis has focused on processes targeting inflammation, cardiomyocyte
89 degeneration, and fibrosis [7–9], whilst only a few studies have addressed the direct
90 effect of viral infection on cardiomyocyte function. Importantly, viruses can also directly
91 cause defective cardiomyocyte contraction, by time-dependently modulating numerous
92 cardiac ion-channels, leading to alterations in action potential duration and resting
93 membrane potential, as well as alterations in calcium loading which may contribute to
94 viral-induced cardiac dysfunction [10–12]. Furthermore, non-structural matrix proteins in
95 the heart can influence a myriad of processes during cardiac stress, such as inflammation,
96 fibrosis and myocyte survival. Our group has previously demonstrated that the non-
97 structural matrix proteins thrombospondin-2 and osteoglycin can affect inflammation,

98 fibrosis and myocyte survival of the heart during cardiac aging, pressure overload,
99 myocardial infarction, as well as after viral myocarditis [13–17] Recently we
100 demonstrated that SPARC protects against adverse cardiac inflammation by preserving
101 the endothelial glycocalyx during viral myocarditis [15]. Interestingly, we found clear
102 differences in QTc times in SPARC KO mice as compared to WT mice during infection
103 despite similar heart rates [15]. These data, in addition to our previous observation that
104 SPARC overexpression leads to an increase in cardiac fractional shortening (FS) and
105 ejection fraction, led us to investigate whether extracellular SPARC can act as an inotropic
106 agent and influence cardiomyocyte contraction in health and during disease.
107

108 Materials and Methods

109 Mouse models

110 The Animal Care and Use Committee of the University of Leuven approved all described
111 study protocols (ECD 243/2013). All animal studies conformed to the Guide for the Care
112 and Use of Laboratory Animals. The Committee for Experiments on Animals of KU
113 Leuven University, Belgium approved experiments. Animal handling was in accordance
114 with the European Directive for the Protection of Vertebrate Animals used for
115 Experimental and Other Scientific Purposes (2010/63/EU). For SPARC overexpressing
116 experiments, an adenoviral vector designed by Barker *et al*. was used[18]. Adenovirus was
117 produced by HEK293 cells that were collected and purified as previously described [19].

118 $1x10^{10}$ adenoviral PFU containing GFP or SPARC was injected into the tail of 12 week old
119 C57Bl6 mice.

120 For viral myocarditis (VM) experiments, 3-5 week old male susceptible C3H mice (Harlan,
121 Boxmeer, The Netherlands) were inoculated intraperitoneally with 10^3 or 10^4 PFU CVB3
122 (Nancy Strain) or PBS. Adenoviral overexpression experiments used the adenoviral vector
123 designed by Barker *et al*. $1x10^{10}$ adenoviral PFU containing GFP or SPARC was injected
124 into the tail vein of 3 weeks old mice 2 weeks prior to the CVB3 inoculation. For SPARC
125 administration experiments, mice were subcutaneously infused for 72 hours with SPARC
126 (40µg/kg/d) or vehicle (PBS) by Alzet osmotic minipump 1003D. Pump implantation
127 surgery was performed as previously described [20] under ketamine and xylazine
128 anesthesia at a dose of 100 mg/kg and 10 mg/kg respectively, and all efforts were made
129 to minimize suffering. In all experiments, mice were sacrificed by a lethal injection of
130 ketamine and xylazine (100mg/kg ketamine and 10mg/kg xylazine) intraperitoneally,
131 plasma was collected, and hearts were removed and prepared for either myocyte
132 isolation or histological and molecular analysis.

133 Echocardiography analysis

134 Mice were anesthetized (2% isoflurane, ecuphar) and echocardiograpy was performed at
135 indicated time points by transthoracic echocardiography with a 13-MHz transducer (i13L,
136 GE ultrasound; Horton Norway) on a Vingmed Vivid 7 scanner (GE ultrasound, Horton,
137 Norway). LV diameters at end-diastole (EDD), and end-systole (ESD), were measured, and
138 fractional shortening (FS) was calculated.

Adult mouse cardiac myocyte isolation and cell shortening experiments

Mice were injected with heparin (1000 U/kg intraperitoneally) and sacrificed by a lethal injection of ketamine and xylazine (100mg/kg ketamine and 10mg/kg xylazine) intraperitoneally. The heart was excised and cannulated via the aorta. Hearts were then mounted onto a Langendorff perfusion setup and initially briefly rinsed with normal Tyrode solution, containing (mM): 137 NaCl, 5.4 KCl, 0.5 $MgCl_2$, 1 $CaCl_2$, 11.8 Hepes, 10 2,3-Butanedione monoxime and 10 glucose, pH was adjusted to 7.4 with NaOH. Subsequently it was perfused with a Ca^{2+}-free solution for 8 min. The Ca^{2+}-free Tyrode solution contained (mM): 130 NaCl, 5.4 KCl, 1.2 KH_2PO_4, 1.2 $MgSO_4$, 6 Hepes, 10 2,3-Butanedione monoxime, 20 glucose, and pH was adjusted to 7.2 with NaOH. Collagenase II (672Units/ml, Worthington 4176) added to the Ca^{2+}-free solution was subsequently perfused for 8 min. The enzyme was then washed out for a further 3 mins with 0.09mM $CaCl_2$ and 50mg/ml BSA 0.18 mM $CaCl_2$. The heart was then removed from the Langendorff perfusion setup, and the myocytes were further dissociated mechanically by gentle shaking. Ca^{2+} was reintroduced stepwise.

Cell shortening was measured using video-edge detection (Ionoptix) during electrical field stimulation at 1 and 2 Hz. Field stimulation was achieved with 5 ms square pulses of constant voltage, at 20 % above threshold. The cell shortening is expressed as the fractional shortening, i.e. normalized to resting cell length, ΔL/L0*100%. During field stimulation cells were superfused with normal Tyrode solution at 37°C. [Ca2+]i was

160 measured with fluo-3, and is reported as the fluorescence normalized to baseline values,
161 after background subtraction, F/F0. To measure the effect of SPARC *ex vivo* on cells,
162 recombinant SPARC (1µg/ml) was added to half of the freshly isolated cell suspension,
163 while the other half was left in normal Tyrode solution. Additionally, to assess the effects
164 of integrin-linked kinase (ILK) inhibition, CPD-22 (Calbiochem; 1µM) was utilized, whilst to
165 investigate the effect of myosin light chain kinase (MLCK) inhibition, ML-7 was used
166 (Sigma Aldrich; 3 µM). For all of the above interventions myocytes were incubated with
167 the specific agent(s) for 1 hour and then cell shortening was measured as described
168 above.

169 In vitro experiments with adult rat cardiac myocytes

170 Cardiac myocytes were isolated by enzymatic dissociation from adult Wistar rat hearts as
171 previously described [21]. Experiments were performed in accordance with the Guide for
172 the Animal Care and Use Committee of the VU University Medical Center (VUmc) and with
173 approval of the Animal Care Committee of the VUmc. For experiments, freshly isolated
174 cardiomyocytes were cultured at 37°C overnight on polyarcrylamide gels (25%
175 Acrylamide40%, 13% Bis2%) with a stiffness of approximately 15kPa. Prior to culture,
176 these gels were coated with laminin (10µg/ml), collagen (50µg/ml) with and without
177 recombinant SPARC (1µg/ml, PeproTech 120-36) in 0.1M HEPES, overnight at 4°C. The
178 cardiac myocytes were plated in plating medium (M199 medium, Gibco, 31150-022, with
179 1% Peniciline-Streptavidine and 5% fetal bovine serum) onto the coated gels, and after 1
180 hour incubation at 37°C, medium was replaced to culture medium (M199 medium with

181 1% Peniciline-Streptavidine, 0.2% Insulin Transferrin Sodium selenite and 0.1%
182 Cytochalasin D). After overnight incubation at 37°C, unloaded cell shortenings of the
183 adherent cardiac myocytes were measured in the culture medium, using different
184 frequencies of electrical field stimulation and analyzed using IonOptix software (IonOptix
185 LLC, Milton, MA). Data are presented as fractional shortening (% diastolic length), time to
186 peak of contraction (TTP) and 50% relaxation time (RT50).

187 Determining gel stiffness

188 Stiffness of fully hydrated gels was determined using a Piuma Nano-indentor (Optics 11,
189 Amsterdam, the Netherlands) in combination with an indentation probe with a stiffness
190 of 1 N/m and a tip radius of 44 um (Optics 11, Amsterdam, the Netherlands). The gel's
191 Young's modulus was determined by averaging 9 individual measurements.

192 Histology and microscopy

193 Cardiac tissue was processed and histochemical and immunohistochemical analyses were
194 performed as previously described [22–24] , and all morphometric analyses were done
195 on sections with myocyte in cross-sectional images. Hematoxylin and eosin – stained
196 sections (4 µm) were used to assess overall morphology. The number of CD-45 – staining
197 cells (monoclonal rat antibody, BD, 553076, clone 30-F11, 5µg/ml) was measured per
198 mm^2. Myocyte cross-sectional areas were calculated by measuring the inner
199 circumference of 150 myocytes per sample on laminin– stained sections (rabbit antibody,
200 Sigma, L9393, 125µg/ml). To assess the amount and cross-linking of fibrosis, Picro Sirius
201 Red staining was performed as previously described [24,25]. Microscopic analyses were

202 performed using a microscope (Leitz DMRXE; Leica), and QWin morphometry software
203 (Leica). All analyses were performed according to standard operating procedures.

204 Immunostaining of isolated cardiac myocytes

205 Adult cardiac myocytes were isolated from healthy mice as described, fixed in 2% PFA in
206 PBS for 10 min, incubated in 50mM glycine for 30 min to remove auto-fluorescence
207 caused by PFA at 488nm, and subsequently stained for SPARC (polyclonal goat antibody,
208 R&D systems, AF492, 5µg/ml) overnight at 4°C. The next day cells were initially incubated
209 with a secondary donkey-anti goat-alexa 488 labeled antibody for 90min. at room
210 temperature and some cells were subsequently stained for integrin beta1 (monoclonal
211 rat antibody, BD, 553715, 0.5µg/ml) for 4 hours at room temperature and afterwards
212 incubated with a secondary goat-anti rat-alexa 568 labeled antibody for 90min. at room
213 temperature. Cells were visualized with confocal microscopy on a Zeiss LSM700
214 microscope (Leica) using the Zen software (Leica), or analyzed using a BD FACSAria III flow
215 cytometer (Becton Dickinson (BD), San Jose, CA) and FlowJo software (Ashland, Oregon).

216 Immunostaining of the coated matrices

217 Matrices were produced and coated as described previously and stored at 4°C prior to
218 staining. Matrices were washed with PBS and subsequently stained for SPARC (polyclonal
219 goat antibody, R&D systems, AF491, 5µg/ml), laminin (polyclonal rabbit antibody, Sigma,
220 L9393, 5µg/ml) and collagen (monoclonal rat antibody, Merck Millipore, MAB 1912,
221 1/100) overnight at 4°C. The next day matrices were incubated with a secondary donkey-
222 anti goat-alexa 660, goat-anti rabbit-alexa 568 and, goat-anti rat-alexa 488 labeled

223 antibodies for 90min. at room temperature and matrices were visualized with confocal
224 microscopy on a Zeiss LSM700 microscope (Leica) using the Zen software (Leica).

225 Myocyte fractionation

226 Adult cardiac myocytes were isolated from healthy mice as described, incubated in lysis
227 buffer, containing (mM): 5 TrisHCl, 5 NaCl, 2 EDTA, 1 $CaCl_2$, 1$MgCl_2$, 2 DTT and pH was
228 adjusted to 7.4. Phosphatase inhibitors (2%, Sigma, P044 and P5726) and protease
229 inhibitors (4%, Roche, 11697498001) were added to the buffer, and cells were incubated
230 overnight at 4°C. The next day, the cell suspension was centrifuged for 1 hour at 4°C and
231 supernatant was collected as cytoplasmic fraction, the pellet was dissolved in lysis buffer
232 and collected as the membrane fraction.
233

234 Immunoprecipitation

235 For immunoprecipitation, left ventricular tissue or isolated cardiomyocytes were lysed in
236 immunoprecipitating buffer containing (mM): 150 NaCl, 20 Tris, 5 EDTA, 1% Triton X-100
237 and pH was adjusted to pH 7.5 using NaOH. Phosphatase inhibitors (2%, Sigma, P044 and
238 P5726) and protease inhibitors (4%, Roche, 11697498001) were added to the buffer.
239 Dynabeads M-280 (Sheep anti rabbit a-Ig, Life Technologies, 2018-06) were washed with
240 lysis buffer and incubated with SPARC antibody (monoclonal rabbit antibody, Sino
241 Biological Inc, 50494-R001, 3ug in 200uL buffer) or rabbit serum as negative control, for
242 2 hours at 4°C. Next, beads were washed and incubated with lysates overnight at 4°C. The
243 next day, the non-bound lysates were collected and resolved for SDS-PAGE, beads were

244 washed and beads-bound immune complexes were resolved for SDS-PAGE. Samples were
245 subsequently immunoblotted for the detection of ILK (polyclonal rabbit antibody, CST,
246 3862, 1/1000).

247 Western Blotting

248 Proteins were isolated from left ventricular tissue, or from isolated cardiomyocytes,
249 separated by SDS-PAGE and subsequently immunoblotted for the detection of pAkt
250 (monoclonal rabbit antibody, Cell signaling, 4060, 1/1000), and total Akt (polyclonal rabbit
251 antibody, Cell signaling, 9272, 1/1000), SPARC (polyclonal goat antibody, R&D systems,
252 AF492, 5µg/ml) and GAPDH (monoclonal mouse antibody, Fitzgerald, 10R-G109a, clone
253 6C5, 0.1µg/ml) overnight at 4°C. Signals were visualized using Hyperfilm ECL (Amersham
254 Biosciences) and quantified using Image J software.

255 Statistics

256 Data were expressed as the mean ± SEM. Histological and molecular analyses in sham-
257 operated and VM groups were performed in independent groups. For echocardiographic
258 measurements, analyses were performed in independent groups, except for the
259 experiment where SPARC or vehicle was infused with an osmotic minipump for 72h,
260 where repeated measures were performed. Normal distribution of all continuous
261 variables was tested according to the method of Kolmogorov and Smirnov. An unpaired
262 Student t-test for 2 groups or ANOVA, followed by a Bonferroni post hoc test for more
263 groups was used in most of the comparisons when groups passed the normality test.

264 When the standard deviation of two groups significantly differed, a Mann-Whitney test
265 for 2 groups or a Kruskal-Wallis test, followed by a Dunn's post hoc test for more groups,
266 was used. A paired Student's t test was used to analyze baseline and follow-up
267 echocardiographic measurements, a Wilcoxon test was used when data did not pass
268 normality test. A two-sided p-value of ≤ 0.05 was considered statistically significant.

269

270 Results

271

272 Extracellular SPARC increases cardiomyocyte contraction

273 To study how extracellular SPARC can improve cardiac function, we investigated whether
274 extracellular SPARC directly interacts with the cardiomyocytes. SPARC presence on the
275 cardiomyocyte increased when cells were isolated and incubated with 1mg/ml SPARC ex
276 vivo for 1h, as compared to cells incubated in normal buffer without SPARC (Figure 1A).
277 These SPARC-incubated cells demonstrated a higher cardiomyocyte cell shortening
278 (Figure 1B and C), with no significant changes in contraction times (TTP) or relaxation
279 times (RT50) (Supplementary Figure 1A and B). To mimic more *in vivo* conditions, we
280 coated matrices with physiological stiffness with laminin and collagen (Lam+Col) or
281 laminin, collagen and SPARC (Lam+Col+SPARC) (Figure 1G). SPARC, a known collagen-
282 binding protein, co-localized with collagen on the matrices (Figure 1D) and importantly,
283 the presence of SPARC did not alter matrix stiffness (Figure 1E). Next, we isolated
284 cardiomyocytes from adult rats and cultured them overnight on these matrices. When

285 stimulated at 0.5, 1 and 2 Hz, rat cardiomyocytes cultured on SPARC-containing matrices
286 demonstrated an increased cardiomyocyte shortening at all frequencies when compared
287 to cells cultured on matrices without SPARC (Figure 1F), while, once again, both TTP and
288 RT50 were unchanged (Supplementary Figure 1C and D).
289
290 Using Western Blot, we demonstrate SPARC presence in the membrane fraction, yet
291 absence in the cytosolic fraction of isolated cardiomyocytes (Figure 1G). Using
292 immunostaining and confocal microscopy we confirmed SPARC's presence on the
293 membrane of the cardiac myocyte, where it co-localizes with integrin-beta1 (Figure 1H).
294 Furthermore, immuno-precipitation demonstrated an interaction of SPARC with integrin-
295 linked kinase (ILK) in both whole LV samples and in isolated cardiomyocytes (Figure 1I).
296
297 To investigate whether this SPARC-induced increased cardiomyocyte cell shortening is
298 through ILK-signaling, we incubated cells in the presence of SPARC and/or the ILK-
299 inhibitor CPD-22. Importantly, the SPARC-induced increased cardiomyocyte cell
300 shortening is blunted in the presence of the ILK-inhibitor (Figure 1J). These results indicate
301 that SPARC increases cardiomyocyte cell shortening, at least in part, through ILK signaling.
302 Notably, CPD-22 alone did not affect cardiomyocyte shortening (Figure 1J).
303
304 In conclusion, these results demonstrate a direct binding of SPARC with the
305 cardiomyocyte membrane, where it appears to interact with ILK and is found in close
306 proximity to integrin-beta1. Moreover, SPARC presence on the membrane increases

307 when cells are incubated in the presence of recombinant SPARC, resulting in increased
308 cardiomyocyte contraction, mediated -at least in part- through increased ILK signaling.
309
310

311 SPARC improves cardiomyocyte function in virus-induced heart 312 failure

313 We subsequently investigated whether SPARC was able to improve cardiomyocyte
314 fractional shortening in conditions where function of this cell type is impaired.
315 Considering the influence of SPARC on enhancing collagen cross-linking, we aimed to
316 study the influence of SPARC on cardiomyocyte function *in vivo* in a disease model with
317 limited fibrosis. As we recently observed changes in cardiac function and ventricular
318 conductivity during VM when SPARC was absent, we decided to investigate in further
319 details the effect of SPARC on cardiomyocyte function in this disease setting. Therefore,
320 a low-dose VM model where mice developed minimal fibrosis, allowed us to study the
321 effect of adenoviral mediated SPARC overexpression on cardiac function and
322 cardiomyocyte contraction. In this model 103 PFU CVB3 was injected intraperitoneally,
323 resulting in mild inflammation and fibrosis, and no cardiomyocyte hypertrophy (Figure 2A
324 - D). Yet, cardiac contraction as measured by FS was decreased (Figure 2E), and there was
325 an apparent onset of cardiac dilation suggested by an increased end systolic diameter
326 (ESD) (Figure 2F). Importantly, fractional shortening of isolated cardiomyocytes was also
327 compromised in this model (Figure 2G). Under field stimulation conditions, these

328 cardiomyocytes did not display a prolonged TTP, but RT50 values were significantly
329 increased (Supplementary Figure 2A and B).
330
331 Next, using this low-dose VM model, we systemically injected SPARC with the adenoviral
332 vector with the intention of increasing cardiac SPARC expression (Figure 2H). One week
333 after CVB3 injection, Western Blotting revealed that cardiac SPARC levels were increased
334 in 3 out of the 4 mice from the adenoviral-SPARC injected group when compared to the
335 control adenoviral-GFP injected mice (Supplementary Figure 2C). Five weeks after CVB3
336 injection, higher FS, and preserved ESD was measured in the SPARC overexpressing
337 animals as compared to GFP overexpression (Figure 2I,J), demonstrating that SPARC
338 overexpression prevents the development of cardiac dysfunction in this mild VM model.
339 Importantly, myocyte cross-sectional area, the amount of fibrosis, collagen cross-linking,
340 and the number of CD45 positive cells in the heart did not differ between the 2 groups, 5
341 weeks after CVB3 injection (Table 1). Still, increased fractional shortening was
342 demonstrated by isolated cardiomyocytes from SPARC-overexpressing animals as
343 compared to isolated cardiomyocytes from control GFP overexpressing animals (Figure
344 2K), indicating a protective, or positive inotropic effect of SPARC at the level of the
345 cardiomyocyte. Notably, no effect on contraction or relaxation times was observed
346 (Supplementary Figure 2E and F). Furthermore, despite SPARC being a Ca^{2+}- binding
347 protein, we could not find indications that SPARC influenced Ca^{2+}-handling, as there were
348 no differences in the Ca^{2+} transient peak heights (Figure 2L), TTP or RT50 (Supplementary
349 Figure 3G and H) of these isolated myocytes. Moreover, we did not find any differences

350 in Akt phosphorylation between LV samples from both groups, which is known to increase
351 intracellular Ca^{2+}-availability and enhance contraction [26], in LV samples from both
352 groups, as shown by Western Blotting (Figure 2M), further supporting no immediate role
353 for SPARC in Ca^{2+}-handling. Taken together, these data demonstrate a protective effect
354 of SPARC on cardiomyocyte function prior to the establishment of virus-induced heart
355 failure. Furthermore, these data indicate that SPARC affects filament sensitivity to Ca^{2+}
356 rather than altering Ca^{2+} handling within the cell.
357
358 We next wanted to assess the therapeutic potential for SPARC, using a high-dose CVB3
359 model with pronounced cardiac inflammation and fibrosis and severely compromised
360 cardiac function (Figure 3A-F). In this model, a higher dose of CVB3 (10^4 PFU CVB3) was
361 injected intraperitoneally in mice, resulting in severe cardiac inflammation after 1 week,
362 and prominent fibrosis and cardiomyocyte hypertrophy after 5 weeks (Figure 3A - D).
363 Here, cardiac function was even more compromised, as shown by severely decreased FS
364 (Figure 3E), and significantly increased ESD, indicating cardiac dilation in this model
365 (Figure 3F). To investigate the therapeutic potential of SPARC, we infused mice with
366 SPARC or vehicle for 72h implanting an osmotic minipump 5 weeks after initial viral
367 exposure, when dilated cardiomyopathy with severe inflammation and fibrosis had been
368 established and measured cardiac function prior and after 72h of SPARC or vehicle
369 infusion (Figure 3G). We found an increased FS in the SPARC treated group, while FS in
370 the vehicle group continued to decline (Figure 3H). End diastolic diameter (EDD) was
371 slightly smaller in the SPARC group prior to treatment, compared to the vehicle group.

372 However, EDD did not change due to the SPARC treatment, while in the vehicle group
373 EDD were slightly decreased after 72h. ESD, on the other hand, was not different between
374 groups or time-points (Figure 3I). Moreover, myocyte cross-sectional area and the
375 amount of CD45 positive cells in hearts did not differ between the 2 groups (Table 2). Yet,
376 while the amount of fibrosis did not differ, collagen cross-linking was increased in the
377 SPARC-treated group as compared to the vehicle group (Table 2), confirming the
378 previously demonstrated effect of SPARC on collagen-crosslinking. Nevertheless, despite
379 this higher collagen cross-linking, we found next to increased cardiac contraction, a trend
380 to increasing shortening in isolated cardiomyocytes from these SPARC-treated mice at
381 2Hz pacing cycle length when compared to cells isolated from vehicle-treated mice (Figure
382 3J), with no differences in TTP or RT50 (Supplementary Figure 2I and J). In addition, when
383 cardiomyocytes were isolated from these severely sick, untreated mice, incubation of the
384 cells with SPARC for 1h *ex vivo* resulted in a significant increase in cardiomyocyte
385 shortening, compared to control cells (Figure 3K), again without influencing TTP or RT50
386 (Supplementary Figure 2K and L).
387
388 Finally, when we infused healthy adult mice with SPARC or vehicle for 72h, we also found
389 increased FS compared to baseline measurements and compared to vehicle-mice (Figure
390 3L). SPARC administration caused decreased end-systolic diameters (ESD), but not end-
391 diastolic diameters (EDD), while diameters did not change in hearts of vehicle-mice
392 (Figure 3M) Again, SPARC administration did not affect cardiomyocyte hypertrophy, the
393 amount of fibrosis, collagen cross-linking, or the amount of CD45 cells (Table 3)

394 # Discussion

395 To our knowledge this study is the first to demonstrate a direct role for a non-structural
396 matrix protein on cardiomyocyte contraction, via interactions of this protein with
397 intracellular effectors. Our previous study on SPARC in myocardial infarction suggested a
398 previously unexplored potential inotropic function for SPARC in the heart. Here, we
399 demonstrated increased cardiac contraction when SPARC was overexpressed, not only in
400 infarcted mice, but also in sham-operated mice [5] yet how SPARC might directly affected
401 cardiomyocyte contraction remained undetermined. Therefore, in this study we aimed to
402 explore the role of SPARC on cardiomyocyte contractility using various *ex vivo* and *in vivo*
403 models. We have shown that extracellular SPARC increases cardiomyocyte contraction,
404 during both health and disease, possibly by interacting with the integrin-beta1-ILK
405 complex on the cardiomyocyte membrane. Not only is SPARC able to prevent a decrease
406 in cardiac function, but it is also able to rescue myocytes that are already compromised
407 through viral infection. These data highlight the potential of SPARC as a therapy in VM
408 and potentially in other disease states where cardiac function is equally compromised.
409

410 Earlier research by Barker and colleagues has demonstrated the interaction of SPARC with
411 integrin-beta1 resulting in increased contractile signalling in lung fibroblasts through
412 activation of ILK. Using SPARC null and WT cells they showed that SPARC is required for
413 fibronectin-induced ILK-activation, which resulted in increased contractile signalling
414 through MLC phosphorylation in these pulmonary fibroblasts [18]. In cardiomyocytes,
415 MLC2v has been identified to be a critical regulator of cardiomyocyte contraction, by

416 promoting actin-myosin interaction [27]. Our current working hypothesis is that SPARC
417 increases cardiomyocyte contraction through its interaction with the integrin-beta1-ILK
418 complex at the cardiomyocyte membrane. As a consequence, MLC phosphatase activity
419 decreases intracellularly and hence ultimately increases the phosphorylation of MLC2v,
420 causing increased actin-myosin interaction and thus augmented cardiomyocyte
421 contraction (Figure 4). In line with Barker *et al.* [18] we have demonstrated an inotropic
422 function of SPARC but this time in cardiomyocytes. SPARC increases cardiomyocyte
423 fractional shortening possibly through its interaction with integrin-beta1 and increased
424 downstream ILK signalling. Further studies will be required, however, to fully elucidate
425 this mechanism.
426
427 Interestingly, in a study using monoclonal antibodies and peptides, the copper-binding
428 domain of SPARC was identified to be required for the interaction of SPARC with integrin-
429 beta1, resulting in increased ILK signalling. In the latter study, stressed lens epithelial cells
430 displayed improved survival *in vitro* due to this interaction [28]. Mooney and colleagues
431 also demonstrated improved survival through intergrin-beta1 signalling in mesangial
432 cells, however SPARC failed to promote survival in this model.[29]
433
434 In the present study we did not investigate a potential protective effect of SPARC on
435 myocyte survival, however we could not find evidence for decreased stress in VM hearts
436 of SPARC overexpressing or SPARC treated mice, as was shown by equal amounts of
437 fibrosis and CD45 positive cells, and the absence of cardiomyocyte hypertrophy in both

438 subsets of hearts. Furthermore, SPARC overexpression did not result in altered levels of
439 phosphorylated Akt, which is known to regulate cardiomyocyte hypertrophy and
440 apoptosis [30,31]. On the other hand, we did see a slight reduction in leukocyte
441 infiltration in SPARC overexpressing hearts, 1 week after CVB3 infection. So if SPARC
442 would provide any protective effect during VM, it is most likely through affecting
443 leukocyte infiltration into the heart, and not by directly promoting cardiomyocyte
444 survival.
445
446 Furthermore, we also demonstrate a rapid effect of SPARC on collagen cross-linking *in*
447 *vivo* as collagen cross-linking is augmented in VM hearts with severe fibrosis, but not in
448 VM hearts with little fibrosis or in healthy hearts, after 3 days of SPARC administration.
449 Importantly, FS in the heart and of the isolated cardiomyocytes was higher in all animals
450 which were administered SPARC.
451

452 **Conclusions**

453 In conclusion, this study is the first to demonstrate a novel inotropic function for SPARC
454 in the healthy heart, possibly by interacting with the integrin-beta1 on the cardiomyocyte
455 membrane and resulting in altered downstream contractile signaling. Moreover, we have
456 demonstrated the benefit of SPARC on contractile forces after coxsackie virus induced
457 cardiac injury, which emphasizes the potential therapeutic application of this agent under
458 these conditions, and perhaps provides proof of concept that this protein could also be
459 of therapeutic benefit in other cardiac diseases where contractile function is diminished.

460 **Funding**

461 This work was supported by a CARIM-funded PhD grant, and by the European
462 Commission's grants FIBROTARGETS [602904], MEDIA [261409], and ARENA [CVON
463 2011]. DMJ was funded by a postdoctoral fellowship from the FWO.

464 # References

465 1. Chen H, Huang XN, Stewart AFR, Sepulveda JL. Gene expression changes associated
466 with fibronectin-induced cardiac myocyte hypertrophy. Physiol Genomics. 2004;18:
467 273–283. doi:10.1152/physiolgenomics.00104.2004

468 2. Harris BS, Zhang Y, Card L, Rivera LB, Brekken RA, Bradshaw AD. SPARC regulates
469 collagen interaction with cardiac fibroblast cell surfaces. Am J Physiol Heart Circ
470 Physiol. 2011;301: H841-847. doi:10.1152/ajpheart.01247.2010

471 3. Bradshaw AD, Sage EH. SPARC, a matricellular protein that functions in cellular
472 differentiation and tissue response to injury. J Clin Invest. 2001;107: 1049–1054.
473 doi:10.1172/JCI12939

474 4. Murphy-Ullrich JE, Sage EH. Revisiting the matricellular concept. Matrix Biol.
475 2014;37: 1–14. doi:10.1016/j.matbio.2014.07.005

476 5. Schellings MWM, Vanhoutte D, Swinnen M, Cleutjens JP, Debets J, van Leeuwen
477 REW, et al. Absence of SPARC results in increased cardiac rupture and dysfunction
478 after acute myocardial infarction. J Exp Med. 2009;206: 113–123.
479 doi:10.1084/jem.20081244

480 6. Mason JW. Myocarditis and dilated cardiomyopathy: an inflammatory link.
481 Cardiovasc Res. 2003;60: 5–10.

482 7. Corsten MF, Schroen B, Heymans S. Inflammation in viral myocarditis: friend or
483 foe? Trends Mol Med. 2012;18: 426–437. doi:10.1016/j.molmed.2012.05.005

484 8. Hazebroek M, Dennert R, Heymans S. Virus infection of the heart--unmet
485 therapeutic needs. Antivir Chem Chemother. 2012;22: 249–253.
486 doi:10.3851/IMP2047

487 9. Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis--diagnosis,
488 treatment options, and current controversies. Nat Rev Cardiol. 2015;12: 670–680.
489 doi:10.1038/nrcardio.2015.108

490 10. Kaese S, Larbig R, Rohrbeck M, Frommeyer G, Dechering D, Olligs J, et al.
491 Electrophysiological alterations in a murine model of chronic coxsackievirus B3
492 myocarditis. PLoS ONE. 2017;12: e0180029. doi:10.1371/journal.pone.0180029

493 11. Steinke K, Sachse F, Ettischer N, Strutz-Seebohm N, Henrion U, Rohrbeck M, et al.
494 Coxsackievirus B3 modulates cardiac ion channels. FASEB J. 2013;27: 4108–4121.
495 doi:10.1096/fj.13-230193

496 12. Wessely R, Klingel K, Santana LF, Dalton N, Hongo M, Jonathan Lederer W, et al.
497 Transgenic expression of replication-restricted enteroviral genomes in heart
498 muscle induces defective excitation-contraction coupling and dilated
499 cardiomyopathy. J Clin Invest. 1998;102: 1444–1453. doi:10.1172/JCI1972

500 13. Deckx S, Heggermont W, Carai P, Rienks M, Dresselaers T, Himmelreich U, et al.
501 Osteoglycin prevents the development of age-related diastolic dysfunction during

502 pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biol.
503 2018;66: 110–124. doi:10.1016/j.matbio.2017.09.002

504 14. Papageorgiou A-P, Swinnen M, Vanhoutte D, VandenDriessche T, Chuah M, Lindner
505 D, et al. Thrombospondin-2 prevents cardiac injury and dysfunction in viral
506 myocarditis through the activation of regulatory T-cells. Cardiovasc Res. 2012;94:
507 115–124. doi:10.1093/cvr/cvs077

508 15. Rienks M, Carai P, van Teeffelen J, Eskens B, Verhesen W, Hemmeryckx B, et al.
509 SPARC preserves endothelial glycocalyx integrity, and protects against adverse
510 cardiac inflammation and injury during viral myocarditis. Matrix Biol. 2018;74: 21–
511 34. doi:10.1016/j.matbio.2018.04.015

512 16. Swinnen M, Vanhoutte D, Van Almen GC, Hamdani N, Schellings MWM, D'hooge J,
513 et al. Absence of thrombospondin-2 causes age-related dilated cardiomyopathy.
514 Circulation. 2009;120: 1585–1597. doi:10.1161/CIRCULATIONAHA.109.863266

515 17. Van Aelst LNL, Voss S, Carai P, Van Leeuwen R, Vanhoutte D, Sanders-van Wijk S, et
516 al. Osteoglycin prevents cardiac dilatation and dysfunction after myocardial
517 infarction through infarct collagen strengthening. Circ Res. 2015;116: 425–436.
518 doi:10.1161/CIRCRESAHA.116.304599

519 18. Barker TH, Baneyx G, Cardó-Vila M, Workman GA, Weaver M, Menon PM, et al.
520 SPARC regulates extracellular matrix organization through its modulation of

521 integrin-linked kinase activity. J Biol Chem. 2005;280: 36483–36493.
522 doi:10.1074/jbc.M504663200

523 19. He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B. A simplified system for
524 generating recombinant adenoviruses. Proc Natl Acad Sci USA. 1998;95: 2509–
525 2514.

526 20. Heymans S, Corsten MF, Verhesen W, Carai P, van Leeuwen REW, Custers K, et al.
527 Macrophage microRNA-155 promotes cardiac hypertrophy and failure. Circulation.
528 2013;128: 1420–1432. doi:10.1161/CIRCULATIONAHA.112.001357

529 21. Kaestner L, Scholz A, Hammer K, Vecerdea A, Ruppenthal S, Lipp P. Isolation and
530 genetic manipulation of adult cardiac myocytes for confocal imaging. J Vis Exp.
531 2009; doi:10.3791/1433

532 22. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, et al.
533 Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac
534 rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med.
535 1999;5: 1135–1142. doi:10.1038/13459

536 23. Lutgens E, Daemen MJ, de Muinck ED, Debets J, Leenders P, Smits JF. Chronic
537 myocardial infarction in the mouse: cardiac structural and functional changes.
538 Cardiovasc Res. 1999;41: 586–593.

539 24. Vanhoutte D, Schellings MWM, Götte M, Swinnen M, Herias V, Wild MK, et al.
540 Increased expression of syndecan-1 protects against cardiac dilatation and

541 dysfunction after myocardial infarction. Circulation. 2007;115: 475–482.
542 doi:10.1161/CIRCULATIONAHA.106.644609

543 25. Junqueira LC, Bignolas G, Brentani RR. Picrosirius staining plus polarization
544 microscopy, a specific method for collagen detection in tissue sections. Histochem
545 J. 1979;11: 447–455.

546 26. Cittadini A, Monti MG, Iaccarino G, Di Rella F, Tsichlis PN, Di Gianni A, et al.
547 Adenoviral gene transfer of Akt enhances myocardial contractility and intracellular
548 calcium handling. Gene Ther. 2006;13: 8–19. doi:10.1038/sj.gt.3302589

549 27. Sheikh F, Lyon RC, Chen J. Getting the skinny on thick filament regulation in cardiac
550 muscle biology and disease. Trends Cardiovasc Med. 2014;24: 133–141.
551 doi:10.1016/j.tcm.2013.07.004

552 28. Weaver MS, Workman G, Sage EH. The copper binding domain of SPARC mediates
553 cell survival in vitro via interaction with integrin beta1 and activation of integrin-
554 linked kinase. J Biol Chem. 2008;283: 22826–22837. doi:10.1074/jbc.M706563200

555 29. Mooney A, Jackson K, Bacon R, Streuli C, Edwards G, Bassuk J, et al. Type IV
556 collagen and laminin regulate glomerular mesangial cell susceptibility to apoptosis
557 via beta(1) integrin-mediated survival signals. Am J Pathol. 1999;155: 599–606.

558 30. Chaanine AH, Hajjar RJ. AKT signalling in the failing heart. Eur J Heart Fail. 2011;13:
559 825–829. doi:10.1093/eurjhf/hfr080

560 31. Terada Y, Inoshita S, Hanada S, Shimamura H, Kuwahara M, Ogawa W, et al.
561 Hyperosmolality activates Akt and regulates apoptosis in renal tubular cells. Kidney
562 Int. 2001;60: 553–567. doi:10.1046/j.1523-1755.2001.060002553.x

563

564 # Figure Legends

565

566 **Figure 1. SPARC improves cardiomyocyte contraction through its interaction with**
567 **integrin-beta1**

568 A FACS analysis demonstrates increased SPARC staining when cardiomyocytes were
569 isolated and incubated with SPARC *ex vivo* for 1h, as compared to cells incubated in
570 normal buffer without SPARC.

571 B,C Isolated adult mouse cardiomyocytes displayed higher FS after 1h incubation with
572 SPARC, compared to cells incubated in normal tyrode buffer.

573 D,E Matrices with physiological stiffness were coated with laminin and collagen (Lam
574 + Col) or laminin, collagen and SPARC (Lam + Col + SPARC). SPARC co-localized with
575 collagen on these matrices, but did not affect matrix stiffness.

576 F Adult rat cardiomyocytes were isolated and cultured on these matrices. Cells
577 cultured on SPARC containing matrices displayed higher fractional shortening (FS),
578 compared to cells cultured on matrices coated with L+C alone.

579 G SPARC is present in the membrane fraction, and absent in the cytosolic fraction of
580 isolated cardiomyocytes, as demonstrated by Western Blotting.

581 H Using immunostaining and confocal microscopy we confirmed SPARC presence on
582 the cardiomyocyte membrane, where it colocalizes with integrin-beta1.

583 I SPARC immunoprecipitation (I.P.) demonstrates interaction with integrin-linked
584 kinase (ILK) in LV samples and in isolated cardiomyoctes.

585 J Isolated adult mouse cardiomyocytes were incubated in the presence of SPARC
586 and/or the ILK-inhibitor CPD-22. The increased FS observed in cells incubated with SPARC
587 was abolished in the presence of CPD-22.
588 A-C N=4 mice and n >4 cells per mouse, D-F N= 3 rats and >20 cells per rat, J N = 3 rats
589 and >4cells per rat, bars panel D 100um, bars panel H 10um, *p<0.05, **p<0.01
590

591 **Figure 2. SPARC improves cardiomyocyte function in a mild model of virus-induced**
592 **heart failure**
593 A - D A mild VM mouse models is used, where mice are injected with10^3 PFU CVB3
594 intraperitoneally. This results in moderate cardiac inflammation after 1 week), little
595 fibrosis and no cardiomyocyte hypertrophy after 5 weeks.
596 E,F Viral infection caused decreased FS and increased ESD.
597 G Contraction of isolated cardiomyocytes is also compromised after virus-infection.
598 H SPARC is overexpressed with the use of an adenovirus, 2 weeks before mild CVB3
599 inoculation.
600 I,J 5 weeks after CVB3 injection, higher FS were measured in the SPARC
601 overexpressing group, with no differences in EDD, and slightly smaller ESD.
602 K Isolated myocytes from the SPARC-overexpressing hearts remained their
603 increased shortening capacities as compared to isolated myocytes from control GFP-
604 hearts.
605 L,M There were no differences in the Ca^{2+} transient peak heights, or levels of Akt
606 phosphorylation.

607 A-F n= 11 for sham and n=13 for VM, G n= 11 for sham and n=13 for VM and >3 cells per
608 mouse, H-J n=12 for advGFP group and n= 11 for advSPARC group, K,L n=12 for advGFP
609 group and n= 11 for advSPARC group and >3cells per mouse, M n=3 for both groups, bar
610 1000um for H&E and Sirius Red stainings, 100um for CD45 and laminin stainings, *p<0.05,
611 **p<0.01, ***p<0.001, ****p<0.0001

612

613 **Figure 3. SPARC has therapeutic potential in severely virus-induced heart failure**

614 A - D In the more severe VM model mice are injected with 10^4 PFU CVB3, which results
615 in severe cardiac inflammation after 1 week, and prominent fibrosis, but no
616 cardiomyocyte hypertrophy after 5 weeks.

617 E, F Viral infection caused severely decreased FS and dilation of the heart.

618 G Mice were infused with SPARC or vehicle for 72h, 5 weeks after high-dose CVB3
619 inoculation, when dilated cardiomyopathy with severe inflammation and fibrosis had
620 been established.

621 H FS was increased in the SPARC treated group, while FS in the vehicle group
622 continued to decline.

623 I EDD were slightly smaller in the SPARC group prior to treatment, compared to the
624 vehicle group, but did not change due to the SPARC treatment, while in the vehicle group
625 EDD were slightly decreased after 72h. ESD were not different between groups or
626 between time-points.

627 J FS was increased in isolated cardiomyocytes from SPARC-treated mice when
628 compared to cells isolated from vehicle-treated mice.

629 K When cardiomyocytes were isolated from the severely sick, untreated mice,
630 incubation of the cells with SPARC for 1h *ex vivo* also resulted in increased FS, compared
631 to control cells.
632 L,M Also healthy mice demonstrated higher FS when SPARC was administered for 72
633 hours, compared to vehicle-administered mice. This resulted in decreased ESD but not
634 decreased end-diastolic diameters EDD in SPARC-administered mice, while diameters did
635 not change in vehicle-administered mice.
636 A-F n=11 for sham and n=13 for VM, G-I n=6 for VM+vehicle and n=7 for VM+SPARC, J n=6
637 for VM+vehicle and n=7 for VM+SPARC and >3cells per mouse, K n=13 for both groups
638 and >3cells per mouse, L,M n=11 for sham+vehicle and n=8 for sham+SPARC, bar 1000um
639 for H&E and Sirius Red stainings, 100um for CD45 and laminin stainings, *p<0.05,
640 **p<0.01, ***p<0.001, ****p<0.0001
641
642 **Figure 4. Proposed mechanism on how SPARC improves cardiomyocyte contraction.**
643 Our working hypothesis is that SPARC interacts with integrin-beta 1 and ILK on the
644 cardiomyocyte membrane. This results in increased ILK signaling, blocking myosin light
645 chain phosphatase (MLCP), and in this way increasing MLC phosphorylation and thus
646 contraction.
647

648

649 **Table 1. Histological analysis of VM mice with GFP or SPARC adenoviral**
650 **overexpression**

	5 weeks VM	
	AdvGFP (n=10)	**AdvSPARC (n=8)**
Myocyte cross-sectional area (μm^2)	217± 6	224 ± 7
Fibrosis (%)	2.4 ± 0.2	2.6 ± 0.4
Orange-red/ yellow-green fibers	1.15 ± 0.17	1.61 ± 0.14
CD45+ cells / mm^2	6.67 ± 2.73	6.57 ± 3.0

651

652

653 **Table 2. Histological analysis of VM mice with 72h vehicle or SPARC**
654 **infusion**

	5 weeks VM + 72h vehicle (n ≥ 5)	5 weeks VM + 72h SPARC (n ≥ 6)
Myocyte cross-sectional area (μm^2)	260 ± 10	253 ± 13
Fibrosis (%)	15.2 ± 2.1	20.3 ± 2.6
Orange-red/ yellow-green fibers	1.28 ± 0.09	2.14 ± 0.21**
CD45+ cells / mm^2	57.5 ± 8.3	84.1 ± 3.8

655 **p<0.01 vs. vehicle

656

657 **Table 3. Histological analysis of hearts after 72h vehicle or SPARC**
658 **administration**

	Vehicle (n ≥ 6)	SPARC (n ≥ 4)
Myocyte cross-sectional area (μm^2)	237 ± 12	252 ± 29
Fibrosis (%)	3.1 ± 0.4	2.9 ± 0.4
Orange-red/ yellow-green fibers	0.54 ± 0.07	0.55 ± 0.05
CD45+ cells / mm^2	13.81 ± 5.65	10.34 ± 9.94

659

660 # Supporting Information

661

662 ## Supplementary Figure 1.

663 A,B Incubation of isolated adult mouse cardiomyocytes with recombinant SPARC for
664 1h *ex vivo* does not affect contraction – and relaxation times (TTP and RT50).
665 C,D TTP and RT50 are not altered in rat cardiomyocytes grown on a matrix with SPARC.
666 A,B N=4 mice and >4 cells per mouse, C,D N = 3 rats and >20 cells per rat

667

668 ## Supplementary Figure 2.

669 A, B Viral infection does not influence TTP but increases RT50 in isolated
670 cardiomyocytes from virus-infected mice.
671 C cardiac SPARC is almost significantly overexpressed in the adenoviral-SPARC
672 injected group when compared to the control adenoviral-GFP injected mice, as shown by
673 Western Blotting.
674 D Slightly decreased cardiac inflammation, as measured by the amount of CD45
675 positive cells, was seen in the SPARC overexpressing group.
676 E,F No effect on contraction or relaxation times was observed when SPARC was
677 overexpressed.
678 G,H There were no differences in the Ca^{2+} transient peak TTP or RT50 in cells from the
679 SPARC overexpressing VM mice.

680 I, J Cardiomyocytes from SPARC-treated mice demonstrated no differences in TTP or
681 RT50.
682 K,L When cardiomyocytes were isolated from severely sick, untreated mice,
683 incubation of the cells with SPARC for 1h *ex vivo* did not influence TTP or RT50.
684 A,B n= 11 for sham and n=13 for VM and >3 cells per mouse , C n=4 for both groups, D
685 n=5 for both groups, E-H n=12 for advGFP group and n= 11 for advSPARC group and
686 >3cells per mouse, I,J n=6 for VM+vehicle and n=7 for VM+SPARC, K,L n=13 for both
687 groups and >3cells per mouse
688

Figure 1


A
SPARC
Vehicle
Count
FITC-A :: AF488 spark FITC-A
B
vehicle
SPARC
relative cell shortening
1.05
1.00
0.95
0.90
1 s
C
Vehicle
+ 1h SPARC ex vivo
cardiomyocyte shortening (%)
**
p = 0.07
1Hz
2Hz
D
Laminin Collagen SPARC
E
Matrix stifness (kPa)
Lam + Col
Lam + Col + SPARC
F
Lam + Col
Lam + Col + SPARC
cardiomyocyte shortening (%)
**
**
*
0.5 Hz
1 Hz
2 Hz
G
membrane
cytosol
SPARC (43kD)
H
SPARC
Integrin b1
Merged
I
LV input
LV SPARC IP
LV SPARC depleted
LV IgG control IP
LV IgG control depleted
CM input
CM SPARC IP
CM SPARC depleted
ILK (51kD)
J
cardiomyocyte shortening (%)
**
**
**
Baseline
SPARC
ILK Inhibitor
ILK Inhibitor + SPARC

689

Figure 2



690

691

692

Figure 3



693

694

Figure 4


Extracellular Matrix
SPARC
β1
α
ILK
Contraction
Actin
P
MLC2v
Myosin
MLCP
Cardiomyocyte

695

Supplementary Figure 1



696

Supplementary Figure 2



697